Autonomic Nervous System Drugs Practice Questions

Q: Side effects of Pilocarpine include:

Ciliary spasm. ***Ciliary spasm*** - **Pilocarpine** is a **direct-acting cholinergic agonist** that stimulates muscarinic receptors, leading to **ciliary muscle contraction**. - This contraction causes **accommodation spasm** (ciliary spasm), resulting in blurry vision, particularly at a distance. *Decreased lacrimation* - **Pilocarpine** actually **increases lacrimation** (tear production) due to its parasympathomimetic effects on the lacrimal glands. - Decreased lacrimation would be an anticholinergic effect, the opposite of pilocarpine's action. *Cycloplegia* - **Cycloplegia** refers to the **paralysis of the ciliary muscle**, leading to loss of accommodation, and is caused by **anticholinergic agents**. - **Pilocarpine**, as a cholinergic agonist, causes **ciliary muscle contraction**, which is the opposite of cycloplegia. *Mydriasis* - **Mydriasis** is the **dilation of the pupil** and is caused by **sympathomimetics** or **anticholinergics**. - **Pilocarpine** causes **miosis** (pupil constriction) through the contraction of the iris sphincter muscle.

Q: Beta blockers mask all effects of hypoglycemia except?

Sweating. ***Sweating*** - **Sweating** is a **cholinergic symptom** mediated by the sympathetic nervous system acting on **muscarinic receptors** (via acetylcholine), NOT beta-adrenergic receptors. - Beta-blockers act on **adrenergic receptors only** and therefore **do not mask sweating**. - This makes **sweating the most reliable clinical sign** of hypoglycemia in patients on beta-blocker therapy. - Sweating remains the classic teaching point for symptoms that persist despite beta-blockade. *Palpitations* - **Palpitations** are an **adrenergic symptom** resulting from increased heart rate and contractility, mediated by **beta-1 adrenergic receptors**. - Beta-blockers effectively **mask** this symptom by blocking these receptors, preventing the cardiovascular response to hypoglycemia. *Dizziness* - **Dizziness** is a **neuroglycopenic symptom** resulting from insufficient glucose supply to the brain. - While technically not masked by beta-blockers (as it's not mediated by beta receptors), dizziness represents a **late and dangerous sign** of severe hypoglycemia. - Sweating is the more reliable and **earlier warning sign** that remains detectable in beta-blocked patients. *Tremors* - **Tremors** are an **adrenergic symptom** caused by stimulation of **beta-2 adrenergic receptors** in skeletal muscle. - Beta-blockers, especially non-selective ones, effectively **mask this symptom** by blocking these receptors.

Q: Ocular effects that include mydriasis are characteristic of which of the following drugs?

phenylephrine (alpha agonist). ***phenylephrine (alpha agonist)*** - **Phenylephrine** is a direct-acting **alpha-1 adrenergic agonist** that causes contraction of the **pupillary dilator muscle**, leading to **mydriasis** (pupil dilation). [1] - It is frequently used clinically to dilate pupils for **ophthalmologic examinations** due to its selective action on alpha-1 receptors in the eye. [2] *neostigmine (cholinesterase inhibitor)* - **Neostigmine** inhibits acetylcholinesterase, increasing acetylcholine at the neuromuscular junction and muscarinic receptors. This leads to **miosis** (pupil constriction), not mydriasis. - Its ophthalmic use is primarily for treating **glaucoma** by improving aqueous humor outflow through cholinergic effects on the ciliary muscle. *phentolamine (alpha blocker)* - **Phentolamine** is a **non-selective alpha-adrenergic antagonist** that blocks both alpha-1 and alpha-2 receptors. - Alpha-1 receptor blockade in the eye would relax the pupillary dilator muscle, leading to **miosis** or prevention of mydriasis, not its induction. *mecamylamine (ganglionic blocker)* - **Mecamylamine** is a **ganglionic blocker** that antagonizes nicotinic receptors in both sympathetic and parasympathetic ganglia. - Blocking parasympathetic ganglia can cause some mydriasis, but ganglionic blockers have widespread, non-selective autonomic effects and are not primarily used for isolated mydriasis.

Q: Shortest-acting non-depolarizing muscle relaxant is:

Mivacurium. ***Mivacurium*** - **Mivacurium** is an intermediate-acting **non-depolarizing** neuromuscular blocker due to its rapid metabolism by **plasma cholinesterases**, making it the shortest-acting among the non-depolarizing agents available [1, 2]. - Its short duration of action (12-18 minutes) allows for quicker recovery of muscle function, which can be advantageous for **short surgical procedures** or for rapid control of muscle relaxation when precise timing is crucial [2]. *Succinylcholine* - **Succinylcholine** is a **depolarizing** neuromuscular blocker, not non-depolarizing, and has a very rapid onset and ultra-short duration of action (5-10 minutes) but acts through a different mechanism by mimicking acetylcholine. - Its use is associated with several side effects, including **malignant hyperthermia**, **hyperkalemia**, and **muscle pain**, which differ from those of non-depolarizing agents. *Atracurium* - **Atracurium** is an intermediate-acting non-depolarizing muscle relaxant that undergoes **Hofmann elimination** and **ester hydrolysis** for metabolism, giving it a duration of action of approximately 20-35 minutes, which is longer than mivacurium [1]. - While suitable for patients with renal or hepatic impairment due to its unique metabolism, it can cause **histamine release**, leading to hypotension or bronchospasm [2]. *Vecuronium* - **Vecuronium** is an intermediate-acting non-depolarizing muscle relaxant with a duration of action of about 25-40 minutes and is primarily eliminated by the liver and kidneys. - It is known for its **cardiovascular stability** as it does not cause histamine release or significant hemodynamic changes, but its longer duration makes it less ideal when very short-acting relaxation is needed.

Q: Which of the following is the shortest-acting competitive neuromuscular blocking agent?

Mivacurium. ***Mivacurium*** - Mivacurium is characterized by its **rapid onset** and **ultrashort duration** of action, primarily due to its hydrolysis by plasma pseudocholinesterase [3]. - This rapid metabolism makes it highly suitable for procedures requiring **brief neuromuscular blockade** or when rapid recovery is desirable. *Atracurium* - Atracurium has an **intermediate duration** of action and is primarily metabolized by **Hofmann elimination**, a non-enzymatic chemical degradation, and ester hydrolysis [3]. - While it's useful in patients with renal or hepatic dysfunction, its duration is significantly longer than mivacurium [4]. *Rocuronium* - Rocuronium is an **intermediate-acting** neuromuscular blocking agent known for its **rapid onset** of action, making it a common choice for **rapid sequence induction** [1]. - Its duration of action is longer than mivacurium and it is primarily eliminated by the kidneys and liver [2]. *Cisatracurium* - Cisatracurium is an **intermediate-acting** neuromuscular blocker that is an isomer of atracurium [3]. - It also undergoes **Hofmann elimination**, but it is more potent and produces fewer histamine release issues than atracurium, yet its duration is still longer than mivacurium [3].

Q: The α2 agonist used in glaucoma is:

Brimonidine. ***Correct: Brimonidine*** - **Brimonidine** is an **α2-adrenergic agonist** commonly used in the treatment of glaucoma - It works by reducing **aqueous humor production** and increasing **uveoscleral outflow**, thereby lowering intraocular pressure - Available as eye drops (0.1%, 0.15%, 0.2% concentrations) *Incorrect: Guanfacine* - **Guanfacine** is an **α2A-adrenergic agonist** primarily used to treat **attention deficit hyperactivity disorder (ADHD)** and **hypertension** - It does not have a primary role in glaucoma treatment *Incorrect: Guanabenz* - **Guanabenz** is an **α2-adrenergic agonist** that acts centrally to reduce **sympathetic outflow**, used mainly as an **antihypertensive agent** - It is not indicated for the treatment of glaucoma *Incorrect: Tizanidine* - **Tizanidine** is an **α2-adrenergic agonist** primarily used as a **muscle relaxant** to manage spasticity - It is not used for glaucoma

Q: Which of the following acts on the trabecular meshwork and increases aqueous outflow?

Pilocarpine. ***Pilocarpine*** - As a **muscarinic agonist**, pilocarpine contracts the **ciliary muscle**, which pulls on the scleral spur. - This action widens the spacing within the **trabecular meshwork**, increasing aqueous humor outflow. *Timolol* - Timolol is a **beta-blocker** that reduces the production of aqueous humor by the ciliary body. - It does not directly affect the structure or function of the trabecular meshwork to enhance outflow. *Brimonidine* - Brimonidine is an **alpha-2 adrenergic agonist** that reduces aqueous humor production and increases uveoscleral outflow. - It does not primarily act on the trabecular meshwork to facilitate outflow. *Brinzolamide* - Brinzolamide is a **carbonic anhydrase inhibitor** that decreases aqueous humor production by the ciliary body. - Its mechanism of action does not involve directly affecting the trabecular meshwork's outflow capacity.

Q: In an animal model, the phenomenon of vasomotor reversal of Dale can be demonstrated by which of the following?

Blocking alpha-1 followed by stimulation of beta-2. ***Blocking alpha-1 followed by stimulation of beta-2*** - **Dale's vasomotor reversal** occurs when the typical pressor response to epinephrine is converted to a depressor (vasodilator) response. This phenomenon is demonstrated by first blocking **alpha-1 adrenergic receptors** (e.g., with phenoxybenzamine or phentolamine), and then administering **epinephrine**. - With alpha-1 receptors blocked, epinephrine cannot cause vasoconstriction. Instead, its stimulation of **beta-2 receptors** is unmasked, leading to vasodilation and a drop in blood pressure—the opposite of the usual pressor response. - This is the classic demonstration of Dale's vasomotor reversal in animal models. *Stimulation of alpha-1 followed by stimulation of beta-2* - Simultaneous stimulation of **alpha-1** and **beta-2 receptors** (as occurs with endogenous epinephrine without any blockade) typically results in a net **vasoconstrictor effect** due to the dominance of alpha-1 signaling in most vascular beds. - This scenario represents the normal response to epinephrine, not a reversal phenomenon. *Stimulation of alpha-1 followed by block of beta-2* - Stimulating **alpha-1 receptors** while blocking **beta-2 receptors** would enhance **vasoconstriction**, as the vasodilatory effects of beta-2 activation would be removed. - This would intensify the normal pressor effect, which is opposite to Dale's reversal. *Stimulation of beta-1 receptor followed by block of beta-2 receptor* - Stimulation of **beta-1 receptors** primarily affects the heart (increasing heart rate and contractility), while blocking **beta-2 receptors** would remove peripheral vasodilation. - Neither action directly relates to the **vasomotor reversal phenomenon**, which specifically involves reversing the vascular response to adrenergic agonists from vasoconstriction to vasodilation.

Q: The mechanism of action of botulinum toxin primarily involves disruption of:

Neuromuscular transmission. ***Neuromuscular transmission*** - **Botulinum toxin** acts at the **neuromuscular junction**, specifically targeting proteins involved in **neurotransmitter** (acetylcholine) release. - It cleaves **SNARE proteins** (SNAP-25, synaptobrevin, syntaxin), thereby preventing the fusion of synaptic vesicles with the presynaptic membrane and the subsequent release of **acetylcholine**, leading to muscle paralysis. - This is the primary and most specific mechanism of action of botulinum toxin produced by *Clostridium botulinum*. *Muscle transmission* - This option is too general; while muscle function is affected, the primary disruption is at the **junction between nerves and muscles**, not directly within the muscle fiber itself. - The toxin's action is on the **presynaptic nerve terminal**, preventing the signal from reaching the muscle, rather than interfering with the muscle's internal contraction mechanism. *Non-neuromuscular transmission* - This is incorrect as **botulinum toxin** specifically targets and disrupts the process of **neuromuscular transmission**, not non-neuromuscular pathways. - Its effects are localized to the **cholinergic nerve terminals**, which are abundant at neuromuscular junctions. *Neural transmission* - While it affects parts of the nervous system, stating "neural transmission" is too broad. The toxin is highly specific to the **peripheral cholinergic nerve terminals** at the neuromuscular junction, not general neural transmission throughout the central or peripheral nervous system. - It does not disrupt the conduction of action potentials along the nerve axon but rather the **release of neurotransmitters** at the synapse.

Q: Alpha-1a adrenergic blocker giving symptomatic relief in benign prostatic hyperplasia (BPH) is:

Tamsulosin. ***Tamsulosin*** - **Tamsulosin** is a **uroselective alpha-1a adrenergic blocker** primarily targeting alpha-1a receptors in the prostate and bladder neck, causing relaxation of smooth muscle and improving urine flow with minimal impact on blood pressure. - This selectivity makes it highly effective for **symptomatic relief of BPH** with a lower risk of orthostatic hypotension compared to non-selective alpha-blockers. *Doxazosin* - **Doxazosin** is a **non-selective alpha-1 adrenergic blocker** that acts on alpha-1 receptors in both the prostate and peripheral vasculature. - While effective for BPH, its non-selectivity leads to a higher incidence of **orthostatic hypotension** and dizziness compared to tamsulosin, as it also lowers blood pressure significantly. *Tolazoline* - **Tolazoline** is a **non-selective alpha-adrenergic antagonist**, primarily used as a vasodilator to treat pulmonary hypertension and peripheral vascular disease. - It is not indicated for the treatment of BPH and has a different pharmacological profile and significant side effects unrelated to prostatic smooth muscle relaxation. *Prazosin* - **Prazosin** is a **non-selective alpha-1 adrenergic blocker** used to treat hypertension and, off-label, for BPH, but it has a short half-life requiring multiple daily doses. - Similar to doxazosin, its non-selective action on vascular smooth muscle can cause significant **first-dose syncope** and orthostatic hypotension, making it less favorable for BPH treatment compared to uroselective agents.

Question 1

Side effects of Pilocarpine include:

Accepted Answer

Ciliary spasm

Answer

Cycloplegia

Answer

Decreased lacrimation

Answer

Mydriasis

Question 2

Beta blockers mask all effects of hypoglycemia except?

Accepted Answer

Sweating

Answer

Palpitations

Answer

Dizziness

Answer

Tremors

Question 3

Ocular effects that include mydriasis are characteristic of which of the following drugs?

Accepted Answer

phenylephrine (alpha agonist)

Answer

neostigmine (cholinesterase inhibitor)

Answer

phentolamine (alpha blocker)

Answer

mecamylamine (ganglionic blocker)

Question 4

Shortest-acting non-depolarizing muscle relaxant is:

Accepted Answer

Mivacurium

Answer

Atracurium

Answer

Succinylcholine

Answer

Vecuronium

Question 5

Which of the following is the shortest-acting competitive neuromuscular blocking agent?

Accepted Answer

Mivacurium

Answer

Atracurium

Answer

Rocuronium

Answer

Cisatracurium

Question 6

The α2 agonist used in glaucoma is:

Accepted Answer

Brimonidine

Answer

Guanabenz

Answer

Guanfacine

Answer

Tizanidine

Question 7

Which of the following acts on the trabecular meshwork and increases aqueous outflow?

Accepted Answer

Pilocarpine

Answer

Timolol

Answer

Brimonidine

Answer

Brinzolamide

Question 8

In an animal model, the phenomenon of vasomotor reversal of Dale can be demonstrated by which of the following?

Accepted Answer

Blocking alpha-1 followed by stimulation of beta-2

Answer

Stimulation of alpha-1 followed by stimulation of beta-2

Answer

Stimulation of alpha-1 followed by block of beta-2

Answer

Stimulation of beta-1 receptor followed by block of beta-2 receptor

Question 9

The mechanism of action of botulinum toxin primarily involves disruption of:

Accepted Answer

Neuromuscular transmission

Answer

Muscle transmission

Answer

Non-neuromuscular transmission

Answer

Neural transmission

Question 10

Alpha-1a adrenergic blocker giving symptomatic relief in benign prostatic hyperplasia (BPH) is:

Accepted Answer

Tamsulosin

Answer

Tolazoline

Answer

Doxazosin

Answer

Prazosin

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?